Drugs / YKST02
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07498673 | May 2026 → Mar 2027 expected | IgA glomerulonephritis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07512947 | May 2026 → Mar 2028 expected | systemic lupus erythematosus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06574568 | Jun 2024 → Dec 2026 expected | refractory plasma cell neoplasm | Excyte Biopharma Ltd | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07695740 | Sep 2026 → Sep 2029 expected | refractory plasma cell neoplasm | Excyte Biopharma Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YKST02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07512947 ↗ |
| Known as | YKST02 for Injection | “YKST02 for Injection” NCT06574568 ↗ |
| Route | Intravenous | “via intravenous injection.” NCT06574568 ↗ |